Clinical Outcomes of Aflibercept in AMD and DME

What clinical outcomes support aflibercept treatment of wet AMD and diabetic macular edema?

Aflibercept treatment for wet AMD and diabetic macular edema is supported by visual acuity improvements equivalent to ranibizumab and superior to laser photocoagulation, significant anatomical improvements including central retinal thickness reductions and diabetic retinopathy severity improvements, clinically meaningful quality of life gains, and a safety profile comparable to other anti-VEGF agents with the advantage of less frequent dosing.

Abstract

Aflibercept treatment for wet age-related macular degeneration produces visual acuity outcomes equivalent to ranibizumab, with both treatments showing similar mean BCVA changes (within 0.5 letters) and approximately 32% of patients gaining ≥15 letters at one year. Anatomical outcomes were also similar, with comparable proportions achieving dry retina (RR 1.06, 95% CI 0.98 to 1.14) and equivalent choroidal neovascularization area reductions. For diabetic macular edema, aflibercept demonstrated statistically significant superiority over laser photocoagulation, with mean BCVA gains of 10.5-13.6 letters compared to -0.5 to 1.2 letters for laser (p<0.0001), and central retinal thickness reductions of 183-195 μm versus 66-73 μm for laser (p<0.0001). At 148 weeks, 35.8-42.9% of aflibercept-treated eyes gained ≥15 letters versus 13.6-18.9% with laser. Aflibercept showed non-inferiority to bevacizumab (mean improvement 15.0 versus 14.0 letters, p=0.37) and better anatomical outcomes than ranibizumab in real-world practice (central subfield thickness reduction -114.4 μm versus -87.8 μm, p<0.01). Quality of life improved meaningfully in both conditions, with NEI VFQ-25 total score gains of +6.11 points in DME and clinically significant improvements across multiple subscales in wet AMD. The safety profile was comparable to other anti-VEGF agents, with serious systemic adverse events similar to ranibizumab (RR 0.99, 95% CI 0.79 to 1.25) and no new safety signals identified in long-term use. The every-8-weeks maintenance dosing regimen after initial loading reduced treatment burden compared to monthly regimens while maintaining efficacy.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Results

Characteristics of included studies

The systematic review included 10 sources examining aflibercept treatment for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These comprised randomized controlled trials, observational studies, and systematic reviews.

The studies represented diverse designs, with five focusing on wet AMD and five on DME. Most studies were randomized controlled trials, with comparators including ranibizumab, bevacizumab, and laser photocoagulation. Follow-up durations ranged from 52 weeks to 3 years.

Effects

Visual Acuity Outcomes in Wet AMD

Aflibercept demonstrated substantial and sustained visual acuity improvements in wet AMD across multiple studies. In the VIEW trials comparing aflibercept to ranibizumab, all aflibercept regimens were within 0.5 letters of ranibizumab for mean change in BCVA, demonstrating clinical equivalence. At one year, the mean change in BCVA was similar between aflibercept and ranibizumab groups (mean difference -0.15 ETDRS letters, 95% CI -1.47 to 1.17). This similarity persisted at two years, with mean changes of 7.2 letters for aflibercept versus 7.9 letters for ranibizumab.

Visual Acuity Outcomes in Diabetic Macular Edema

Aflibercept demonstrated consistent superiority over laser photocoagulation and non-inferiority to other anti-VEGF agents in DME. In the VISTA and VIVID trials, mean BCVA gains with aflibercept were 12.5 and 10.7 letters versus 0.2 letters with laser in VISTA, and 10.5 and 10.7 letters versus 1.2 letters with laser in VIVID (p<0.0001 for all comparisons).

Anatomical Outcomes

Aflibercept produced significant anatomical improvements in both wet AMD and DME. In wet AMD, the proportion of eyes achieving dry retina (absence of fluid on OCT) was similar between aflibercept and ranibizumab (RR 1.06, 95% CI 0.98 to 1.14). Choroidal neovascularization area reduction showed no significant difference between the two agents (mean difference -0.24 mm², 95% CI -0.78 to 0.29).

For DME, central retinal thickness reductions were substantial and significantly greater than laser photocoagulation:

Vision-Related Quality of Life

Quality of life assessments demonstrated clinically meaningful improvements with aflibercept treatment. In wet AMD, the NEI VFQ-25 scores showed similar improvements across all subscales over 52 weeks for aflibercept 2q8 and ranibizumab, with the greatest improvements in mental health and general vision. For DME, the AQUA study reported substantial quality of life improvements at 52 weeks:

Safety Profile

The safety profile of aflibercept was generally favorable and comparable to other anti-VEGF agents. In wet AMD trials, ocular and systemic adverse events were similar across aflibercept and ranibizumab treatment groups. The Cochrane review reported that serious systemic adverse events were similar between aflibercept and ranibizumab (RR 0.99, 95% CI 0.79 to 1.25).

Treatment Regimens

Aflibercept was administered at a dose of 2 mg across all studies. Two primary dosing regimens emerged:

• Every 4 weeks regimen (2q4): Monthly injections throughout the treatment period.
• Every 8 weeks regimen (2q8): The more common regimen involved 3-5 initial monthly loading doses followed by maintenance dosing every 8 weeks.

Comparative Effectiveness

Aflibercept demonstrated non-inferiority to ranibizumab in wet AMD and superiority to laser photocoagulation in DME, while showing comparable effectiveness to bevacizumab.

Overall, the findings strongly support the use of aflibercept for treating wet AMD and diabetic macular edema, highlighting its effectiveness, safety profile, and quality of life improvements.